

EMPERRA[®] presents convincing efficacy data for its digital diabetes management platform ESYSTA[®]

- Scientific studies with more than 1,200 participants show significant improvement in therapy for diabetes patients

EMPERRA[®] E-Health Technologies is a pioneer in the development of innovative digital health products in the field of diabetes mellitus to improve the care of these patients. The scientific data from three studies with more than 1,200 patients show the convincing effectiveness of the digital diabetes management platform ESYSTA[®]. It can achieve a significant improvement in therapy for insulin-treated diabetes patients. On this basis, EMPERRA[®] is pursuing the reimbursement of ESYSTA[®] as a standard service via the digital health application (DiGA/DiHA) or through contracts with health insurance companies.

EMPERRA[®] has always focused on medical effectiveness, combined with the participation of patients and practitioners through efficient digital networking. **Dr. med. Janko Schildt** (CEO and founder): *"I am delighted that we have now been able to provide comprehensive scientific proof. This means that our digital device-independent platform ESYSTA[®] can be used with a high level of medical evidence for the benefit of patients and to relieve the burden on diabetes treatment teams in our core market of Germany in the long term. This also makes ESYSTA[®] an attractive system for all health insurance companies in terms of health economics."*

Prof. Dr. med. Peter Schwarz (head of the three consecutive study projects of ESYSTA[®] and President of the International Diabetes Federation - IDF) explains: *"Due to its uniqueness, ESYSTA[®] has many starting points for improving treatment, especially for insulin-treated patients in the diabetes mellitus therapy segment. I consider the available positive scientific results to be decisive in the further process towards the extensive prescribability of ESYSTA[®]. The current data show a faster reduction in the long-term marker HbA1c in poorly controlled patients, even in people with diabetes who are included in the so-called disease management programs (DMPs). ESYSTA[®] also has a reinforcing effect when used with GLP-1 analogues (so-called "weight loss injections"). I am confident that these medical effects will also be recognized by experts outside Germany. In a few years' time, we should therefore see ESYSTA[®] as part of the digital standard procedures for the treatment of specific diabetes patient groups, and not just in Germany."*

The diabetes management platform ESYSTA[®] - with its CE approval as a medical device and data and information security in accordance with ISO 27001 - can improve therapy adherence and compliance on the patient side with the ESYSTA[®] app. ESYSTA[®] allows the connection of many blood glucose meters and "smart" insulin pens as well as digital disposable pen caps to the platform. On the healthcare professional's side, seamless, largely automatically collected data is thus transparently available for highly qualified and efficient therapy support via the ESYSTA[®] online portal.

Dr. med. Horst Mertens (COO/CBDO) adds: *"The ESYSTA[®] platform has shown that diabetes management can be easily, safely and digitally integrated into treatment processes. As part of the planned German market launch in Germany, EMPERRA[®] has set itself the goal of generating further scientific data through a large-scale non-interventional study (NIS). The renowned FIDAM (Diabetes Research Institute, Bad Mergentheim) will be involved in this process. Based on this, ESYSTA[®] will also be used in other international projects."*

Press release

EMPERRA® is currently focusing on the application process for a permanent DiHA listing and discussions with health insurance companies and strategic partners. A current financing round is still open for interested investors.

<https://www.emperra.com/>

<https://esysta-diabetes.com/>

Contact:

EMPERRA GmbH -E-Health Technologies
Zeppelinstraße 48a
14471 Potsdam / Germany

Dr. med. Horst Mertens, M.D., MBA / COO and CBDO

P: +4933197934800

E: h.mertens@emperra.com

<https://www.emperra.com/>

Press release

Additional information / Backgrounder:

Management team of EMPERRA® GmbH E-Health Technologies:

Dr. med. Janko Schildt (CEO, Founder) – email: j.schildt@emperra.com - [LinkedIn](#)

Dr. med. Horst Mertens, MBA, MD (COO, CBDO) – email: h.mertens@emperra.com - [LinkedIn](#)

About the integrated diabetes telemonitoring system ESYSTA®:

With the ESYSTA® product system, EMPERRA® distributes the world's first wireless and web-based insulin pen integrated telemonitoring product system in the field of diabetes mellitus. With an addition to the product system based on Bluetooth® and NFC technology, EMPERRA® has significantly expanded the interoperable functionality of ESYSTA®. Around 90% of all devices for diabetes self-management are already integrated into the ESYSTA® platform.

The guiding principle behind the development of ESYSTA® with automated data transfer of all relevant treatment data from different hardware components is simple to use - but groundbreaking. The basic data is transferred fully automatically, mapped and pre-analyzed in an easy-to-understand digital patient diary, the ESYSTA® app, and prepared in a way that is easy for all users to understand using a digital ESYSTA® assistant with a traffic light algorithm, among other features.

Patients or medical practices do not need a transmission cable or special software. ESYSTA® provides an innovative and database-based platform that offers completely new possibilities for tele-diabetology.

Dr. med. Janko Schildt, CEO and founder of EMPERRA®, comments: *"Patients are provided with an efficient tool that significantly simplifies diabetes therapy, both in personal diabetes management and in the self-monitoring of important parameters. Patients' lifestyles are simplified and their quality of life is noticeably improved. The use of ESYSTA® significantly reduces the workload for all users: both the patient and the accompanying private and medical environment. With the existing and future product developments, we are convinced that we will reach an even larger target group and further advance digital healthcare for the benefit of patients, doctors and nursing staff."*

The ESYSTA® system is CE-certified and therefore approved in all EU countries. It meets all legal requirements for data protection and IT security. ESYSTA® automatically records all data relevant to the diabetic. Applied insulin doses (IU), blood glucose values and carbohydrate units (BE/KHE) are wirelessly and automatically transferred in full to a digital patient diary. All data can be traced back over months. A traffic light system signals critical daily values and other conspicuous indicators to the patient and the attending physicians. Adjustments or changes in therapy can therefore be made more quickly. Thanks to its interoperable interfaces, ESYSTA® is also prepared to be integrated into other software systems for digital patient management in the future. This means that ESYSTA® is technologically future-proof.

All relevant data can be accessed at any time on computers, tablets and smartphones (Android/iOS®) via transmission over the mobile network and connection to an internet-based evaluation platform. Potentially any device with a wireless interface can be integrated into ESYSTA® thanks to the interoperable interfaces. This already accounts for over 90% of the German market. This benefits not only the patients, but also the authorized general practitioners and specialists as well as the treating hospital or nursing staff.

ESYSTA® thus simplifies the implementation of therapy and patient care. Dr. med. Horst Mertens (COO, CBDO): *"With its data and user integration, the ESYSTA® product system also has a positive influence on the psychosomatic and psychosocial aspects of patients' lives that are important for any diabetes therapy. In our accompanying studies, we surveyed so-called soft indicators and found that the self-confidence of ESYSTA® users increased with an equally growing sense of personal responsibility."*

Press release

For years, healthcare expenditure and costs for the widespread, cost-intensive chronic disease diabetes mellitus have been steadily increasing worldwide. On average, one in ten people worldwide suffers from this disease (<https://diabetesatlas.org>). Initial studies also suggest that these costs could be significantly reduced by using ESYSTA .°

Keywords:

Esysta, Emperra, diabetes mellitus, diabetes management system, diabetes platform, tele-monitoring, tele-diabetology, digital health, e-health, digital health application, DiGA, Digital Healthcare Act, DVG, BfArM

Figures 1-3 for further schematic explanation:



Solution: ESYSTA® - Intelligent data-powered diabetes management platform for patients, their relatives and caregivers

Benefits for patients / relatives



- **Guidance, help & self-empowerment**
(via automated diary, algorithms & ESYSTA® assistance)

Benefits for caregivers



- **Improved data insights and interventions**
(automated values for blood glucose + insulin; algorithms)

▶ Improved metabolic status and Quality of Life (QoL)

▶ Optimized patient care and full-sized monitoring 24/7

Outcomes: ESYSTA® Integrated Diabetes Management System

Before



"It opened my eyes, looking at the analysis and seeing how my measuring and injecting behaviour has a direct impact on my blood glucose levels."



After




▶ Top patient guidance with high evidence